Search

Displaying results 1071 - 1080 of 7604 in total
  1. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    [L44096] In April 2026, the FDA approved an expanded indication for teplizumab, lowering the eligible age range from 8 years and older down to 1 year and older for patients with Stage 2 T1D.[L56140] … Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS.

  2. Drug

    Sarecycline

    go.drugbank.com/drugs/DB12035
    ApprovedInvestigational

    nine years of age and older [L4814]. … s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    alpha-Tocopherol succinate

    go.drugbank.com/drugs/DB14001
    ApprovedNutraceuticalVet approved

    At the moment, however, there exists a lack of formal data and evidence to support any such additional indications for vitamin E use. … Alpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements.

    Mixtures: For Men, Dry Form Vitamin E 400iu With Selenium 100mcgCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Narsoplimab

    go.drugbank.com/drugs/DB16418
    ApprovedInvestigational

    and pediatric patients aged 2 years and older. … [A241030] Evidence increasingly points to a role for the complement system in TMA.

  5. Drug

    Lusutrombopag

    go.drugbank.com/drugs/DB13125
    ApprovedInvestigational

    Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … Lusutrombopag is currently in phase III development in various European countries including Austria, Belgium, Germany, and the UK [A36730].

  6. Drug

    Ornidazole

    go.drugbank.com/drugs/DB13026
    Investigational

    Ornidazole has been used in trials studying the prevention of Elective Colorectal Surgery.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: ORNIDONE FORT 500 MG FILM TABLET, 10 ADET, ORNISID FORT 500 MG FİLM KAPLI TABLET, 10 ADET
  7. Drug

    Potassium citrate

    go.drugbank.com/drugs/DB09125
    ApprovedInvestigationalVet approved

    Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis. … Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste.

    Mixtures: Multi-force for Women Tab, Cytra-KCategories: Potassium Salt
  8. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019. … Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared to older

    Categories: Anti-Acne Preparations for Topical Use, Retinoids for Topical Use in Acne
  9. Drug

    Dioxybenzone

    go.drugbank.com/drugs/DB11221
    ApprovedWithdrawn

    Dioxybenzone, or benzophenone-8, is an organic compound derived from [DB01878] that is used as a sunscreen agent. It absorbed UV-B and UV-AII rays. … Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% [L2525].

  10. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    ], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor